Table 2.
Univariate analysis and multivariate analysis
| Univariate analysis | |||
|---|---|---|---|
| Variable | HR | 95% CI | P value |
| Dexamethasone >4 mg | 1.74 | 1.07-2.85 | .03 |
| KPS ≤70 | 2.78 | 1.65-4.66 | .0003 |
| Age (continuous) | 1.05 | 1.01-1.08 | .01 |
| ≤9.0 months from prior whole-brain radiation therapy | 1.40 | 0.87-2.26 | .17 |
| Volume >4 mL | 1.99 | 1.07-3.69 | .02 |
| Leptomeningeal disease | 1.83 | 0.93-3.59 | .08 |
| 10 or more brain metastases | 1.30 | 0.77-2.17 | .33 |
| Largest metastases ≥3 cm | 1.13 | 0.60-2.14 | .70 |
| Systemic disease progressing | 1.12 | 0.66-1.88 | .67 |
| Primary controlled | 0.84 | 0.52-1.35 | .47 |
| Free from extracranial disease | 0.56 | 0.26-1.23 | .15 |
| Small cell histology | 1.55 | 0.82-2.94 | .18 |
| Multivariate analysis | |||
|---|---|---|---|
| Variable | HR | 95% CI | P value |
| Dexamethasone >4 mg | 2.09 | 1.11-3.91 | .02 |
| KPS ≤70 | 2.10 | 1.14-3.87 | .02 |
| Age (continuous) | 1.05 | 1.01-1.08 | .01 |
| Volume >4 mL | 1.94 | 1.04-3.63 | .04 |
Abbreviations: CI = confidence interval; HR = hazard ratio; KPS = Karnofsky performance status.